The preventive effect of Ninjin'yoeito on sarcopenia among patients with advanced urotherial carcinoma who received systemic chemotherapy (A single-center, single-arm, open-label trial)

The preventive effect of Ninjin'yoeito on sarcopenia among patients with advanced urotherial carcinoma who received systemic chemotherapy (A single-center, single-arm, open-label trial) - The preventive effect of Ninjin'yoeito on sarcopenia among patients with advanced urotherial carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044092

Enrollment

Registered

2021-06-01

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced urothelial carcinoma

Interventions

Priscribe Ninjin&#39

yoeito 5-7.5 g/day orally for patients with advanced urothelial carcinoma who recieve platinum-based chemotherapy during 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with advanced urothelial carcinoma who recieve platinum-based chemotherapy (Age; 20-90 years) 2. Patients who understand and are willing to participate this study. 3. Patients without a severe general condition due to progressive disease. 4. Patients without an abnormality in liver function and serum potassium level. 5. Patients who do not take other harbal medicines which have supportive roles for cancer treatment.

Exclusion criteria

Exclusion criteria: 1. Patients can not take a harbal medicine due to dysphagia and/or tube feeding. 2. Patients who have already took other harbal medicines which have supportive roles for cancer treatment.

Design outcomes

Primary

Measure	Time frame
The evaluation of change in the area of psoas muscle 8 weeks after the study.	—

Secondary

Measure	Time frame
The evaluation of change in frailty, body composition, and serum grelin levels 4 and 8 weeks after the study.	—

Countries

Japan

Contacts

Public ContactTeppei Okamoto

Hirosaki University Graduate School of Medicine Department of Urology

t-okamoto@hirosaki-u.ac.jp0172335111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

The preventive effect of Ninjin&#39;yoeito on sarcopenia among patients with advanced urotherial carcinoma who received systemic chemotherapy (A single-center, single-arm, open-label trial)